ESMO Virtual 2020: Circulating tumour DNA in metastatic kidney cancer patients

In a paper presented at this year’s European Society of Medical Oncology (ESMO) 2020 virtual congress, Dr Zeynep Zengin from City of Hope Hospital, Los Angeles, USA presented the results of a study using a commercially available circulating tumour DNA (ctDNA) assay. Assessment of ctDNA is a non-invasive method to assess genetic alterations in tumours. […]

read more

Circulating tumour DNA as a potential prognostic biomarker for immunotherapy

A study published in Nature Cancer showed that blood levels of DNA from solid tumours (circulating tumour DNA or ctDNA) were associated with the prognosis of cancer patients with different types of  tumours who had been treated with pembrolizumab. The study included 94 patients with various solid tumours who were treated with pembrolizumab. ctDNA levels varied […]

read more

Liquid biopsies for kidney cancer

New research from the Medical University of Graz in Austria in collaboration with Cancer Research UK, Cambridge on the detection of tumour DNA in the blood and urine of kidney cancer patients was published in the journal Genome Medicine last month. The detection of circulating tumour DNA (ctDNA) in blood or urine, known as ‘liquid […]

read more
Showing all 3 results
  TOP